Journal of Allergy and Clinical Immunology Global · Published 2026-04-15 · DOI 10.1016/j.jacig.2026.100706
This report highlights the successful use of oral desensitization to manage delayed-type hypersensitivity to afatinib, enabling continuation of treatment for epidermal growth factor receptor–mutated non–small cell lung cancer. In the absence of standardized protocols, it offers valuable insights for managing similar clinical challenges.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →